國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁 到查詢結果 [ subject:"Antineoplastic agents" ]

切換: 標籤 | MARC模式 | ISBD

Cancer drug design and discovery

Neidle, Stephen.

Cancer drug design and discovery

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Cancer drug design and discoveryedited by Stephen Neidle.
其他作者:	Neidle, Stephen.
出版者:	New York, NY :Academic Press,2008.
面頁冊數:	xv, 473 p., [27] p. of plates :ill. (some col.) ;27 cm.
標題:	Antineoplastic agentsDevelopment.
電子資源:	An electronic book accessible through the World Wide Web; click for information
ISBN:	9780123694485

Cancer drug design and discovery
Cancer drug design and discovery[electronic resource] /edited by Stephen Neidle. - 1st ed. - New York, NY :Academic Press,2008. - xv, 473 p., [27] p. of plates :ill. (some col.) ;27 cm.

Includes bibliographical references and index.

Section I. Basic Principles -- 1. Modern cancer drug discovery: Integrating targets, technologies and treatments -- 2. Preclinical pharmacology and in vivo models -- 3. Clinical trial designs for more rapid proof-of-principle and approval -- Section II. Methodology -- 4. Structural biology and anticancer drug design -- 5. Natural product chemistry and cancer drug discovery -- 6. Pharmacokinetics & ADME optimization in drug discovery -- Section III. Drugs in the clinic and laboratory -- 7. Temozolomide: from cytotoxic to molecularly-targeted agent -- 8. Camptothecins for drug design, cancer cell death and gene targeting -- 9. Targeting thymidylate synthase by antifolate drugs for the treatment of cancer -- Section IV. New Agents -- 10. Targeting inactive kinases: structure as a foundation for cancer drug discovery -- 11. Cell cycle inhibitors in cancer: current status and future directions -- 12. Inhibition of DNA repair as a therapeutic target -- 13. Heat shock protein-90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways -- 14. Heat shock protein-90-directed therapeutics and target validation -- 15. Inhibitors of tumour angiogenesis -- 16. The biology and oncology of RAFERK signalling P53 as a therapeutic target -- Section V. The reality of cancer drugs in the clinic -- 17. Cancer drug resistance -- 18. Failure Modes in Anticancer Drug Discovery and Development.

The ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumours. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry, and clinicians taking oncology options. * Covers both currently available drugs as well as those under development * Provides a clinical perspective on trials of new anticancer agents * Presents drug discovery examples through the use of case histories.

Electronic reproduction.
Amsterdam :
Elsevier Science & Technology,
2008.

Mode of access: World Wide Web.

ISBN: 9780123694485

Source: 114525:114618Elsevier Science & Technologyhttp://www.sciencedirect.comSubjects--Topical Terms:

275191
Antineoplastic agents
--Development.Index Terms--Genre/Form:

214472
Electronic books.

LC Class. No.: RS431.A64 / C36 2008eb

Dewey Class. No.: 616.994061

National Library of Medicine Call No.: 2008 A-287

Cancer drug design and discovery
LDR:03915cmm 2200361Ia 4500 001 256664
003 OCoLC
005 20100729101520.0
006 m d
007 cr cn|||||||||
008 100818s2007 enkaf ob 001 0 eng d
020 $a 9780123694485
020 $a 0123694485
029 1 $a NZ1 $b 12541708
035 $a (OCoLC)228148277
035 $a ocn228148277
037 $a 114525:114618 $b Elsevier Science & Technology $n http://www.sciencedirect.com
040 $a OPELS $c OPELS
049 $a TEFA
050 1 4 $a RS431.A64 $b C36 2008eb
060 1 4 $a 2008 A-287
060 1 4 $a QV 269 $b N397c 2008
082 0 4 $a 616.994061 $2 22
245 0 0 $a Cancer drug design and discovery $h [electronic resource] / $c edited by Stephen Neidle.
250 $a 1st ed.
260 $a New York, NY : $b Academic Press, $c 2008.
300 $a xv, 473 p., [27] p. of plates : $b ill. (some col.) ; $c 27 cm.
504 $a Includes bibliographical references and index.
505 0 $a Section I. Basic Principles -- 1. Modern cancer drug discovery: Integrating targets, technologies and treatments -- 2. Preclinical pharmacology and in vivo models -- 3. Clinical trial designs for more rapid proof-of-principle and approval -- Section II. Methodology -- 4. Structural biology and anticancer drug design -- 5. Natural product chemistry and cancer drug discovery -- 6. Pharmacokinetics & ADME optimization in drug discovery -- Section III. Drugs in the clinic and laboratory -- 7. Temozolomide: from cytotoxic to molecularly-targeted agent -- 8. Camptothecins for drug design, cancer cell death and gene targeting -- 9. Targeting thymidylate synthase by antifolate drugs for the treatment of cancer -- Section IV. New Agents -- 10. Targeting inactive kinases: structure as a foundation for cancer drug discovery -- 11. Cell cycle inhibitors in cancer: current status and future directions -- 12. Inhibition of DNA repair as a therapeutic target -- 13. Heat shock protein-90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways -- 14. Heat shock protein-90-directed therapeutics and target validation -- 15. Inhibitors of tumour angiogenesis -- 16. The biology and oncology of RAFERK signalling P53 as a therapeutic target -- Section V. The reality of cancer drugs in the clinic -- 17. Cancer drug resistance -- 18. Failure Modes in Anticancer Drug Discovery and Development.
520 $a The ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumours. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry, and clinicians taking oncology options. * Covers both currently available drugs as well as those under development * Provides a clinical perspective on trials of new anticancer agents * Presents drug discovery examples through the use of case histories.
533 $a Electronic reproduction. $b Amsterdam : $c Elsevier Science & Technology, $d 2008. $n Mode of access: World Wide Web. $n System requirements: Web browser. $n Title from title screen (viewed on May 14, 2008). $n Access may be restricted to users at subscribing institutions.
650 0 $a Antineoplastic agents $x Development. $3 275191
650 0 $a Antineoplastic agents $x Design. $3 221224
650 0 $a Cancer $x Chemotherapy. $3 194707
650 1 2 $a Antineoplastic Agents. $3 226661
650 2 2 $a Drug Design. $3 197549
650 2 2 $a Neoplasms $x drug therapy. $3 345776
655 7 $a Electronic books. $2 local. $3 214472
700 1 $a Neidle, Stephen. $3 454144
710 2 $a ScienceDirect (Online service) $3 307425
776 1 $c Original $z 9780123694485 $z 0123694485 $w (OCoLC)154760280
856 4 0 $3 ScienceDirect $u http://www.sciencedirect.com/science/book/9780123694485 $z An electronic book accessible through the World Wide Web; click for information
994 $a C0 $b TEF